The Spiegel Laboratory works in the area of “Synthetic Immunology,” which integrates synthetic chemistry, immunology, and cell biology toward the development of systems capable of controlling and/or creating human immunity. In particular, the lab has developed a class of antibody-recruiting small molecules (ARMs) that are capable of enhancing recognition of diverse pathogens by the human immune system. We have successfully employed this approach in targeting both HIV and prostate cancer, and are currently expanding its scope toward other diseases as well. Other areas of interest include re-engineering bacteria to perform complex immunological tasks, and investigations into advanced glycation end-products (AGEs), a poorly understood class of immunomodulatory post-translational modifications of proteins.
- Spiegel DA. Synthetic Immunology to Engineer Human Immunity. Nature Chemical Biology. 2010; 6; 871-872. Chosen as one of eight recipients of the 2010 Grand Challenges in Chemical Biology Competition.
- Nelson JW, Chamessian AG, McEnaney PJ, Kazmierczak BI, Spiegel DA. A Biosynthetic Strategy for Re-engineering the S. aureus Cell Wall with Non-Native Small Molecules. ACS Chemical Biology. 2010, 1147-1155.
- Zhang AX, Murelli RP, Barinka C, Michel J, Cocleaza A,** Jorgensen WL, Lubkowski J, Spiegel DA. A Remote Arene-Binding Site on Prostate Specific Membrane Antigen Revealed by Antibody-Recruiting Small Molecules. Journal of the American Chemical Society. 20
- Murelli RM, Zhang AX, Michel J, Jorgensen WL, Spiegel DA. Chemical control over immune recognition: A class of antibody-recruiting small molecules that target prostate cancer. Journal of the American Chemical Society. 2009; 131; 17090-17092.
- Parker CG, Domaoal RA, Anderson KS, Spiegel DA. An antibody-recruiting small molecule that targets HIV gp120. Journal of the American Chemical Society. 2009;131: 16392-16394. This work was featured as a news story in ACS Chemical Biology, 2009, 4, 975.